GANITE
LOE Approachinggallium nitrate
NDAINJECTIONINJECTABLEPriority Review
Approved
Jan 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANITE (gallium nitrate) is an intravenous injectable small molecule approved in 1991 for the treatment of hypercalcemia of malignancy. The drug works by inhibiting bone resorption and reducing serum calcium levels in cancer patients with elevated calcium. It is indicated for patients with symptomatic, life-threatening hypercalcemia unresponsive to hydration.
LOE Approaching
A product in late-stage commercial lifecycle with moderate competitive pressure (30) signals a mature, possibly contracting sales team focused on margin protection rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANITE offers limited external visibility and career mobility given zero linked job postings and a contracting lifecycle stage. Roles are primarily defensive, focused on maintaining market share and navigating LOE rather than driving innovation or team growth.
Account ManagerSales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.